Core Viewpoint - SenesTech, Inc. is initiating a search for a new CEO as current CEO Joel Fruendt plans to retire, with Dr. Jamie Bechtel appointed as Interim Executive Chair to support the transition [1][3]. Group 1: Leadership Transition - Joel Fruendt, who joined SenesTech in 2022, has informed the Board of his intent to retire, and he will remain in his position until a successor is found or until June 30, 2026 [1][2]. - The Board will engage an executive search firm to assist in identifying a qualified successor for the CEO role [4]. Group 2: Interim Leadership - Dr. Jamie Bechtel has been appointed as Interim Executive Chair to support the management team during the transition, focusing on strategic alignment and communication [3][4]. - The current COO Michael Edell and CFO Tom Chesterman will continue to lead day-to-day operations during this transitional period [4]. Group 3: Company Mission and Products - SenesTech is dedicated to humane pest management through fertility control, with its flagship product Evolve® aimed at enhancing pest management effectiveness while reducing reliance on traditional poisons [5]. - The company's mission is to create healthier environments, cleaner cities, and more efficient businesses through sustainable solutions [5].

Company Overview - SenesTech, Inc. is a leader in fertility control for managing animal pest populations, focusing on sustainable alternatives to traditional pest control methods [3] - The company has developed ContraPest®, the first and only U.S. EPA-registered contraceptive for male and female rats, along with Evolve Rat and Evolve Mouse Birth Control, which are FIFRA 25(b) minimum-risk solutions [3] Upcoming Events - SenesTech will participate in a webcast presentation at the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025, at 3:30 p.m. ET [1][2] - The webcast can be accessed through the conference home page or directly via provided links, with a replay available afterward [2] Mission and Vision - The company's mission emphasizes healthier cities, safer environments, and smarter pest management, advocating for reproductive control as the future of pest management [4]

Core Viewpoint - SenesTech, Inc. has reported significant financial improvements in Q4 2024, including a 70% increase in revenue and a strategic focus on operating optimization initiatives aimed at reducing expenses by approximately $2 million annually to accelerate profitability [1][7][6]. Financial Performance - Revenue for Q4 2024 increased by 70% to $501,000 compared to $295,000 in Q4 2023, driven by a 206% growth in e-commerce [5]. - Gross profit margin improved to 60.9% in Q4 2024 from 43.7% in Q4 2023 [5]. - Operating expenses decreased by 16% in Q4 2024 compared to the same quarter in 2023 [5]. - Net loss for Q4 2024 was $1.3 million, an improvement from a net loss of $1.7 million in Q4 2023 [5]. - Adjusted EBITDA loss for Q4 2024 was $1.1 million, down from $1.6 million in Q4 2023 [5]. Key Growth Initiatives - The Evolve™ Rat product line became the largest revenue contributor, accounting for approximately 52% of Q4 2024 revenue [5]. - The Evolve™ Mouse product, launched in May 2024, contributed 24% of Q4 2024 revenue [5]. - The company has expanded its distribution through major online retailers, including Amazon and Walmart [5]. - Municipal programs for rodent contraception have been initiated in cities like New York, Baltimore, Chicago, and Boston [5]. - International distribution agreements have been signed in 10 countries, with product shipments already occurring in several regions [5]. Operating Optimization Initiatives - New initiatives are expected to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven to approximately $7 million from a previous estimate of $12 million [6][8]. - The company aims to enhance operational efficiencies and streamline costs to accelerate its path to profitability [6][8]. Management Commentary - The CEO highlighted the transformational year for SenesTech, emphasizing strong financial results and the smallest quarterly Adjusted EBITDA loss in the company's history [7]. - The management is committed to a focused strategy that targets sustainable long-term success in the multi-billion-dollar rodent control market [8].